@article{Moreno-Torres_I-2021_84687,
title = {Risk and outcomes of COVID-19 in patients with multiple sclerosis},
author = {Moreno-Torres, I. and Lallana, V. and Costa-Frossard, L. and Oreja-Guevara, C. and Aguirre, C. and Suárez, E. and Moreno, M. and Canelo, L. and Muñoz, J. and Aladro, Y. and Cárcamo, A. and García, E. and Cuello, J. and Monreal, E. and Sainz de la Maza, S. and Pérez Parra, F. and Valenzuela Rojas, F. and López de Silanes de Miguel, C. and Casanova, I. and Martínez Gines, M. and Blasco, R. and García, A. and Villar-Guimerans, L. and Fernández-Dono, G. and Elvira, V. and Santiuste, C. and Espiño, M. and García Domínguez, J.},
month = {nov},
year = {2021},
abstract = {Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020. Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.},
pages = {3712-3721},
volume = {28},
issue = {11},
journal = {European Journal of Neurology},
publisher = {Wiley},
url = {https://doi.org/10.1111/ene.14990},
}
